Why we measure it

The clinical value of annual ANA screening lies in its ability to detect the prodromal phase of autoimmune disease — the period before clinical criteria are met, when the immune system has begun producing autoantibodies but overt disease has not yet declared itself. A landmark study by Arbuckle et al., published in the New England Journal of Medicine in 2003, analysed stored blood samples from 130 military personnel who subsequently developed systemic lupus erythematosus (SLE). Autoantibodies characteristic of SLE were detectable in 88% of these individuals before the onset of clinical disease — on average 3.3 years before diagnosis, and in some cases more than nine years before. The study showed a stepwise pattern of autoantibody accumulation: patients began with one autoantibody specificity and progressively accumulated others, with the number and type of autoantibodies predicting which clinical features would develop. Systemic lupus erythematosus (ANA positive in 95–99% of cases), Sjögren's syndrome (70–80%), systemic sclerosis or scleroderma (85–95%), and mixed connective tissue disease (virtually 100%) all have high ANA positivity rates. These conditions are frequently misdiagnosed for years because their early symptoms — fatigue, joint pain, dry eyes, skin changes — are non-specific. A rising titre, a new pattern, or a first-time high-titre positive in the context of symptoms is a clinically meaningful finding that justifies specialist rheumatology review and targeted follow-up testing with specific autoantibody panels (anti-dsDNA, anti-Smith, anti-Ro/SS-A, anti-La/SS-B, anti-Scl-70, anti-centromere).

Why every 12 months

ANA status can change over time. A person who tests ANA-negative at 40 may become seropositive by 46 — and the Arbuckle NEJM data suggests this conversion can precede clinical diagnosis by years. Annual testing captures this transition, providing the longitudinal data needed to determine whether a low-titre positive is stable (and therefore likely a non-pathological finding) or rising (a different signal entirely). It also provides a baseline: a first-time ANA at age 52 of 1:160 with a speckled pattern is interpreted differently in a person who has five prior negative screens than in one presenting without any prior data. Annual measurement converts a single ambiguous reading into a trend with interpretive power.

What movement means

ANA results are reported qualitatively (positive or negative at a given dilution) and quantitatively (the titre at which fluorescence is still detectable). Laboratory methodology — including the specific HEp-2 cell line used, the conjugate, and the fluorescence threshold — varies between institutions, which means titres are not directly comparable across different laboratories. Most laboratories define a positive ANA as a titre ≥ 1:40 or ≥ 1:80. The clinical significance of a positive ANA increases substantially with titre: a 1:40 positive in a healthy adult is statistically common and almost always non-pathological; a 1:640 positive is far more likely to reflect an active autoimmune process. The pattern also matters: a centromere pattern in a patient with Raynaud's phenomenon is a specific association with limited cutaneous systemic sclerosis; a homogeneous pattern at high titre in a young woman with joint pain and fatigue is a specific association with SLE. The number alone, without pattern and clinical context, is incomplete information.

In the protocol